Ab­b­Vie and Gen­mab score ac­cel­er­at­ed fol­lic­u­lar lym­phoma nod for Ep­kin­ly 

Ab­b­Vie and Gen­mab are cel­e­brat­ing their sec­ond ac­cel­er­at­ed ap­proval for Ep­kin­ly, this time in fol­lic­u­lar lym­phoma.

The bis­pe­cif­ic an­ti­body, al­so known as ep­cori­ta­m­ab, was ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.